Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

itrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 What can be ... areas are going to grow at the fastest rates? ... revenues to 2025, assessing data, trends, opportunities and prospects ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
(Date:7/30/2015)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) ... 2015 financial results and provide a corporate update. Arena ... Select Market closes that day. The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/30/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), ... support technologies that are revolutionizing the treatment of ... $73.6 million for the quarter ended June 30, ... ended June 30, 2014.  Currency fluctuations impacted revenue ... points, during the three months ended June 30, ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
... Ore.--(BUSINESS WIRE)--May 1, 2007 - AVI BioPharma, ... of NEUGENE(R) antisense compounds,against seasonal influenza A ... professor, Department of Microbiology and Immunology,Tulane University ... poster,form at the 20th International Conference on ...
... -- CEL-SCI,CORPORATION announces that CEL-1000 alone increased ... that the combination of,CEL-1000 with MAS-1, a ... Pharma, induced highly significant increases,in specific anti-HBV ... by Dr. Daniel Zimmerman, Senior Vice President ...
Cached Medicine Technology:AVI BioPharma Reports Positive Pre-Clinical Influenza Data 2AVI BioPharma Reports Positive Pre-Clinical Influenza Data 3CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response,Against Hepatitis B Antigen in Animals 2
(Date:7/30/2015)... ... 30, 2015 , ... WellSpan Health in York, Pa., has ... claims for bariatric surgery that, despite complying with national and local coverage determinations, ... nurse auditor at WellSpan Health, tells Atlantic Information Services’ (AIS) Report on Medicare ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... the largest amount of research grants in its history of funding brain aneurysm ... professionals who have dedicated their life’s work toward scientific research directed at early ...
(Date:7/30/2015)... ... July 30, 2015 , ... Case Mason ( http://www.casemason.com ... consumer brands, recently completed a consolidation of all of its production capabilities to ... out of two separate locations situated 11 miles apart. , The advantages of ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Breast-Feeding Week (Aug. 1-7) ... children have the nutrition required to grow into healthy adults. Medicationdiscountcard.com ... many prescription pre-natal vitamins. , Folic Acid , Arguably one of the most ...
(Date:7/29/2015)... Francisco, California (PRWEB) , ... July 30, 2015 , ... ... Jimi Hendrix Dorton Arena Raleigh North Carolina concert posters. The same poster art was ... were printed by Globe Poster based in Baltimore and are classic boxing style concert ...
Breaking Medicine News(10 mins):Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4
... rose during the Great Depression, study shows , ... may not be all bad. In fact, U.S. researchers ... University of Michigan researchers looked at death rates during ... 20th century. From the stock market crash of 1929 ...
... women with metastatic colorectal cancer lived longer than younger ... a benefit from estrogen or other hormones, according to ... Research , a journal of the American Association for ... that estrogen prevents colorectal cancer, but this is the ...
... of Texas Health Science Center at Houston and the ... launch a study of Jamaican children that they hope ... may interact to cause autism spectrum disorders. The ... the National Institute of Child Health and Human Development ...
... study finds, , TUESDAY, Sept. 29 (HealthDay News) -- Despite ... know about national recommendations for a minimum of 30 minutes ... goal, a new study has found. , The lack of ... in the United States, the researchers said. Their finding came ...
... Black Women,s Health Study (BWHS) of the Sloan Epidemiology ... received a five-year continuation of grant funding award from ... years 16-20 of the largest follow-up study of the ... associate director of the Slone Epidemiology Center and professor ...
... RIVERSIDE, Calif. A deadly disease, malaria afflicts 350-500 ... a million people. Transmitted by Anopheles mosquitoes, the ... with at least 40 percent of the world,s population ... is the development of an effective malaria vaccine. Yet, ...
Cached Medicine News:Health News:Could the Recession Be Good for Your Health? 2Health News:Could the Recession Be Good for Your Health? 3Health News:Could the Recession Be Good for Your Health? 4Health News:Women fare better than men with metastatic colorectal cancer -- are hormones helping? 2Health News:UT Houston, Jamaica researchers launch autism study 2Health News:UT Houston, Jamaica researchers launch autism study 3Health News:Exercise 30 Minutes a Day? Who Knew! 2Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 2Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 3Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 4
... H 2 O W/O Adapter., ... these humidifier systems feature a dual-purpose reservoir with ... for secure attachment of a humidifier adapter. The ... from reaching oxygen delivery tubing. An audible relief ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
MISTY OX® Hi-Fi Nebulizer...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: